Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $10.4 Million - $12.1 Million
67,100 Added 7.08%
1,015,100 $174 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $40.3 Million - $45.9 Million
-252,000 Reduced 21.0%
948,000 $173 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $57.9 Million - $65.2 Million
420,600 Added 53.96%
1,200,000 $186 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $54.3 Million - $67.6 Million
-410,100 Reduced 34.48%
779,400 $105 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $52.5 Million - $60.5 Million
-363,100 Reduced 23.39%
1,189,500 $190 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $83 Million - $99.6 Million
600,400 Added 63.05%
1,552,600 $251 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $16.3 Million - $18.7 Million
-121,600 Reduced 11.32%
952,200 $128 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $355B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.